cagrilintide CAS 1415456-99-3

Category: A novel glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Usage: Mainly used for blood glucose control in type 2 diabetes. Some studies have shown that it also has potential for weight loss.

Characteristics: By mimicking the action of GLP-1 in the human body, it delays gastric emptying, suppresses appetite, and promotes insulin secretion, thereby reducing blood sugar.

Cagrilintide  is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. 
Cagrilintide alone, as well as cagrilintide in combination with semaglutide have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.